AMGEN®

Pioneering science delivers vital medicines™

2015 Bioinformatics Get-Together

Jacob Justus – Manager, Clinical Applications & Analytical Services

Amgen – The Science



Amgen - FIBCO


Pipeline
19 targets supported by GENETIC VALIDATION
The industry's largest toolkit with 11 MODALITIES*
A mix of INNOVATIVE MOLECULES, POTENTIAL NEW INDICATIONS, AND BIOSIMILARS
A robust and differentiated pipeline, leveraging state-of-the-art science to create medicines for serious illness. Amgen is focused on high-quality candidates that demonstrate large, clinically-relevant effects. Human genetic validation is used whenever possible to enhance the likelihood of success.
Download Pipeline Chart
THERAPEUTIC AREA All
MODALITY All
PHASE ONE
AMG 172
AMG 208
AMG 211
AMG 228
AMG 232
AMG 282
AMG 301
AMG 319
AMG 357
AMG 557
AMG 581
AMG 595
AMG 780
AMG 811
AMG 820
AMG 876
AMG 900
Oprozomib
PHASE TWO
AMG 139
AMG 157
AMG 181
AMG 334
AMG 337
BLINCYTO® (blinatumomab)
Kyprolis® (carfilzomib)
Omecamtiv mecarbil
Oprozomib
XGEVA® (denosumab)
PHASE THREE
AMG 334
Aranesp® (darbepoetin alfa)
BLINCYTO® (blinatumomab)
Etelcalcetide (AMG 416)
Kyprolis® (carfilzomib)
Prolia® (denosumab)
Repatha™ (evolocumab)
Romosozumab
Talimogene laherparepvec
Trebananib
Vectibix® (panitumumab)
XGEVA® (denosumab)
BIOSIMILARS†
ABP 215 (biosimilar bevacizumab)
ABP 494 (biosimilar cetuximab)
ABP 501 (biosimilar adalimumab)
ABP 710 (biosimilar infliximab)
ABP 798 (biosimilar rituximab)
ABP 980 (biosimilar trastuzumab)

R&D - Global Development Operations - CAAS

Bioinformatics Implementation - Metrics, Reporting, & Spotfire Dashboards



For Illustration of tool, Non-Amgen data, taken from: http://semanticommunity.info/Data_Science/Data_Science_for_VIVO, 2015